Charles River Laboratories International, Inc. $CRL Shares Purchased by Danske Bank A S

Posted by Francis Steltz on May 5th, 2026

Danske Bank A S increased its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 96.1% in the 4th quarter, Holdings Channel.com reports. The firm owned 51,016 shares of the medical research company’s stock after purchasing an additional 25,005 shares during the period. Danske Bank A S’s holdings in Charles River Laboratories International were worth $10,177,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of CRL. Cardinal Capital Management lifted its position in Charles River Laboratories International by 0.6% in the fourth quarter. Cardinal Capital Management now owns 10,928 shares of the medical research company’s stock valued at $2,180,000 after purchasing an additional 62 shares during the period. Asset Management One Co. Ltd. lifted its holdings in Charles River Laboratories International by 4.0% in the fourth quarter. Asset Management One Co. Ltd. now owns 1,847 shares of the medical research company’s stock valued at $375,000 after acquiring an additional 71 shares during the period. Hantz Financial Services Inc. lifted its holdings in Charles River Laboratories International by 11.2% in the third quarter. Hantz Financial Services Inc. now owns 793 shares of the medical research company’s stock valued at $124,000 after acquiring an additional 80 shares during the period. Advisory Services Network LLC lifted its holdings in Charles River Laboratories International by 2.6% in the third quarter. Advisory Services Network LLC now owns 3,226 shares of the medical research company’s stock valued at $505,000 after acquiring an additional 83 shares during the period. Finally, Rothschild Investment LLC lifted its holdings in Charles River Laboratories International by 82.4% in the third quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 84 shares during the period. 98.91% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

CRL has been the subject of a number of recent analyst reports. Weiss Ratings reissued a “sell (d)” rating on shares of Charles River Laboratories International in a report on Monday, April 20th. Royal Bank Of Canada began coverage on shares of Charles River Laboratories International in a research report on Tuesday, April 14th. They set an “outperform” rating and a $215.00 price target for the company. Barclays lifted their price target on shares of Charles River Laboratories International from $200.00 to $210.00 and gave the company an “overweight” rating in a research report on Tuesday, April 14th. Evercore reiterated an “outperform” rating on shares of Charles River Laboratories International in a research report on Wednesday, April 8th. Finally, UBS Group lifted their price target on shares of Charles River Laboratories International from $170.00 to $175.00 and gave the company a “neutral” rating in a research report on Wednesday, February 25th. Eleven investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $205.36.

Get Our Latest Research Report on CRL

Charles River Laboratories International Trading Up 3.8%

NYSE:CRL opened at $172.10 on Tuesday. The company has a market capitalization of $8.49 billion, a PE ratio of -58.14, a price-to-earnings-growth ratio of 2.01 and a beta of 1.44. The company has a quick ratio of 1.02, a current ratio of 1.29 and a debt-to-equity ratio of 0.67. Charles River Laboratories International, Inc. has a 52-week low of $113.89 and a 52-week high of $228.88. The stock has a fifty day simple moving average of $169.78 and a 200-day simple moving average of $183.17.

Charles River Laboratories International (NYSE:CRL – Get Free Report) last issued its quarterly earnings data on Wednesday, February 18th. The medical research company reported $2.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.33 by $0.06. Charles River Laboratories International had a positive return on equity of 15.60% and a negative net margin of 3.59%.The firm had revenue of $994.23 million during the quarter, compared to the consensus estimate of $986.98 million. During the same period in the previous year, the firm posted $2.66 EPS. The company’s quarterly revenue was down .8% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. On average, equities research analysts expect that Charles River Laboratories International, Inc. will post 10.97 earnings per share for the current fiscal year.

Charles River Laboratories International Company Profile

(Free Report)

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.